The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock’s price. Do they really matter, though? Let’s take a look at what these Wall Street heavyweights have to ...
Key Points Automakers have negative narratives for being cyclical, capital-intensive, and low-margin. General Motors and Ferrari have both broken free of historically low P/E ratios. Buybacks have been critical to GM’s valuation rise, and that could slow as the stock becomes more expensive. 10 stocks we like better than General Motors › Detroit automakers such ...
Key Points Space Exploration Technologies (NASDAQ: SPCX) offered investors a historic moment this month. The company, more often known as SpaceX, completed the world’s biggest initial public offering and made it a key event for retail investors, earmarking about 20% of the shares for them — individuals like you and me. So, of course, all ...
Key Points While the artificial intelligence (AI) boom has been great for stock market investors over the past few years, there are a few signs that the rally might be getting exhausted. The “Magnificent Seven” stocks, which had been pushing the major averages consistently higher, are all down over the past three years. All of ...
Key Points The S&P 500 Growth index typically outperforms the regular S&P 500 because of its higher exposure to the powerhouse “Magnificent Seven” stocks. But these stocks, which include the likes of Nvidia and Alphabet, delivered a sluggish performance in the first half of 2026. I think the Magnificent Seven stocks will turn around over ...
Shares of Elite Pharmaceuticals, Inc. ELTP have lost 13.7% since the company reported earnings for the fiscal year ended March 31, 2026, underperforming the S&P 500 Index, which gained 1.8% over the same period. The stock has also trailed the broader market over the past month, declining 14.7% compared with the S&P 500’s 1.8% dip. ...
Key Points Cerebras (NASDAQ: CBRS), a producer of AI chips, went public at $185 per share on May 14. Its stock opened at $350, but it now trades at about $205. That’s still 11% above its IPO price, but investors who chased its post-IPO gains are now underwater. Let’s see why Cerebras’ stock fizzled out ...
Key Points If you’ve invested in AMD (NASDAQ: AMD) or Intel (NASDAQ: INTC) over the past year, you’re likely a very happy investor. Intel has risen about 480%, and AMD has risen around 280% over the past 12 months. Those are major gains, but not all stock gains are created equally. Sometimes, stocks go up ...
Key Points Nvidia (NASDAQ: NVDA), the world’s largest producer of data center GPUs, is the linchpin of the booming AI market. Most of the world’s top AI companies use its GPUs to train their large language models (LLMs), and Nvidia locks in those clients with its proprietary software. Nvidia still has a bright future, but ...
Key Points Meta is reportedly building a cloud business that would sell AI computing power, putting it in competition with Amazon Web Services. AWS revenue grew 28% year over year in the first quarter — its fastest growth in 15 quarters. AWS generated $14.2 billion of Amazon’s $23.9 billion in first-quarter operating income. These 10 ...
